Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

iwNHL 2023

The 20th International Workshop on Non-Hodgkin Lymphoma
29 Sep–01 October 2023 | Miami, FL

iwNHL 2023

The 20th International Workshop on Non-Hodgkin Lymphoma
29 Sep–01 October 2023 | Miami, FL

Explore presentations by leading experts from iwNHL 2023 below. Click here to view the roundtable discussion for each of the sessions.

Session 1: T‐cell lymphoma  

Laurence  de Leval
Genomic profiling for clinical decision making in TCL
Laurence de Leval Lausanne University Hospital, Lausanne, Switzerland
François Lemonnier
5‐azacitidine in follicular helper T‐cell lymphomas
François Lemonnier Paris-East Créteil University, Paris, France
Francine  Foss
Therapeutic options for the treatment of PTCLs
Francine Foss Yale, CT, United States

Session 2: Evolving frontline immune‐chemotherapy for MCL and the impact on survival outcomes

Eric Hsi
Biological characteristics of high-risk MCL
Eric Hsi Wake Forest University School of Medicine, Cleveland, OH, United States
Marek  Trněný
Significance of the TRIANGLE trial for MCL
Marek Trněný Charles University Hospital, Prague, Czech Republic
John  Kuruvilla
Future role of ASCT in MCL
John Kuruvilla Princess Margaret Cancer Centre, Toronto, Canada
Stephen Ansell
Do you need to treat young and old MCL patients differently?
Stephen Ansell Mayo Clinic, Rochester, MN, United States
Yucai Wang
Novel agents for relapsed MCL
Yucai Wang Mayo Clinic, Rochester, MN, United States

Session 3: Keynote address

Riccardo Dalla-Favera
Super‐enhancer hypermutation deregulating gene expression in DLBCL
Riccardo Dalla-Favera Columbia University, New York City, NY, United States

Session 4: New pathogenetic mechanisms and therapeutic targets in DLBCL
*please note that no presentations are available from session 4 due to unpublished data

Session 5: Novel therapies part 1 – ADCs & menin inhibitors

Laurie  Sehn
POLARIX – Polatuzumab vedotin
Laurie Sehn BC Cancer Agency, Prince George, Canada
Sven de Vos
Zilovertamab
Sven de Vos David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
Paolo Caimi
Loncastuximab tesirine
Paolo Caimi Cleveland Clinic, Cleveland, OH, United States
Andrew Davies
Camidanlumab tesirine
Andrew Davies University of Southampton, Southampton, United Kingdom
Stephen Ansell
Brentuximab vedotin
Stephen Ansell Mayo Clinic, Rochester, MN, United States
Juan Pablo Alderuccio
Emerging ADCs with novel targets
Juan Pablo Alderuccio University of Miami, Miami, FL, United States
Paolo Caimi
BMF‐219
Paolo Caimi Cleveland Clinic, Cleveland, OH, United States

Session 6: Expanding the CAR platform for NHL

Stephen  Schuster
Tisa-cel
Stephen Schuster Perelman School of Medicine, Philadelphia, PA, United States
Sattva  Neelapu
Axi-cel
Sattva Neelapu University of Texas MD Anderson Cancer Center, Houston, TX, United States
David Maloney
Liso-cel
David Maloney Fred Hutchinson Cancer Research Center, Seattle, WA, United States
John Gerecitano
C-CAR066 & C-CAR039
John Gerecitano Janssen Pharmaceuticals, West New York, NJ, United States
James Essell
CB-010: CD19-directed, PD-1 KO, AlloCAR for R/R B-cell lymphomas
James Essell Oncology Hematology Care, Cincinnati, OH, United States
David Miklos
Repeat CAR-T following failure of a first CD19 CAR-T
David Miklos Stanford University, Stanford, CA, United States
Jason Westin
Expanding CAR T-cells as a second-line therapy for LBCL
Jason Westin The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Tanya  Siddiqi
Allogeneic CAR-T for NHL – fact or fantasy?
Tanya Siddiqi City of Hope, Duarte, CA, United States
Lazaros Lekakis
CAR T-cell therapy in the ‘real world’
Lazaros Lekakis University of Miami, Miami, FL, United States

Session 7: Novel therapies part 2: BTK inhibitors

Mazyar Shadman
Zanubrutinib
Mazyar Shadman Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Marek  Trněný
Acalabrutinib
Marek Trněný Charles University Hospital, Prague, Czech Republic
Nirav Niranjan Shah
Pirtobrutinib
Nirav Niranjan Shah Medical College of Wisconsin, Milwaukee, WI, United States
Tanya  Siddiqi
BTK degraders – NX-2127
Tanya Siddiqi City of Hope, Duarte, CA, United States

Session 8: Bispecifics for NHL

Mazyar Shadman
CD20/CD3 bispecific antibodies
Mazyar Shadman Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Martin  Hutchings
Glofitamab
Martin Hutchings Copenhagen University Hospital, Copenhagen , Denmark
Laurie  Sehn
Mosunetuzumab
Laurie Sehn BC Cancer Agency, Prince George, Canada
Marion Subklewe
Blinatumomab
Marion Subklewe LMU Hospital Munich, Munich, Germany
Krish Patel
Plamotamab
Krish Patel Swedish Cancer Institute, Seattle, WA, United States
Krish Patel
Odronextamab
Krish Patel Swedish Cancer Institute, Seattle, WA, United States
Ranjit Nair
TNB 486
Ranjit Nair MD Anderson Cancer Center, Houston, TX, United States
Martin  Hutchings
Epcoritamab
Martin Hutchings Copenhagen University Hospital, Copenhagen , Denmark

iwNHL 2023 has been supported by: